Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Recommendation of “Moderate Buy” by Analysts

Travere Therapeutics, Inc. (NASDAQ:TVTX) has received a consensus rating of “Moderate Buy” from the fifteen analysts that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $17.85.

Several equities research analysts have recently issued reports on TVTX shares. Guggenheim reaffirmed a “neutral” rating on shares of Travere Therapeutics in a research note on Wednesday, March 27th. Wedbush restated an “outperform” rating and issued a $13.00 price target on shares of Travere Therapeutics in a research report on Wednesday, April 17th. HC Wainwright reiterated a “buy” rating and set a $17.00 price objective on shares of Travere Therapeutics in a research report on Wednesday, March 13th. Piper Sandler raised their target price on shares of Travere Therapeutics from $10.00 to $11.00 and gave the stock a “neutral” rating in a report on Thursday, January 18th. Finally, Wells Fargo & Company upped their price target on shares of Travere Therapeutics from $8.00 to $9.00 and gave the company an “equal weight” rating in a report on Friday, February 16th.

Travere Therapeutics Price Performance

TVTX stock opened at $5.74 on Wednesday. Travere Therapeutics has a 52 week low of $5.25 and a 52 week high of $22.75. The firm has a market capitalization of $436.87 million, a P/E ratio of -3.57 and a beta of 0.58. The company has a fifty day simple moving average of $7.46 and a two-hundred day simple moving average of $7.69. The company has a quick ratio of 3.41, a current ratio of 3.47 and a debt-to-equity ratio of 1.88.

Travere Therapeutics (NASDAQ:TVTX) last announced its earnings results on Thursday, February 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.11. The firm had revenue of $45.06 million for the quarter, compared to analysts’ expectations of $41.25 million. Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%. Analysts anticipate that Travere Therapeutics will post -3.1 earnings per share for the current fiscal year.

Insider Activity

In other Travere Therapeutics news, SVP William E. Rote sold 4,764 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $8.71, for a total value of $41,494.44. Following the completion of the sale, the senior vice president now directly owns 80,720 shares in the company, valued at approximately $703,071.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, SVP William E. Rote sold 4,764 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $8.71, for a total value of $41,494.44. Following the completion of the sale, the senior vice president now owns 80,720 shares in the company, valued at approximately $703,071.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Christopher R. Cline sold 3,818 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.53, for a total transaction of $32,567.54. Following the completion of the sale, the chief financial officer now directly owns 70,903 shares of the company’s stock, valued at approximately $604,802.59. The disclosure for this sale can be found here. Over the last quarter, insiders sold 34,773 shares of company stock valued at $300,625. Corporate insiders own 4.06% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Signaturefd LLC boosted its position in Travere Therapeutics by 1,656.4% during the fourth quarter. Signaturefd LLC now owns 3,021 shares of the company’s stock valued at $27,000 after purchasing an additional 2,849 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Travere Therapeutics by 968.1% in the 4th quarter. Nisa Investment Advisors LLC now owns 5,650 shares of the company’s stock valued at $51,000 after buying an additional 5,121 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Travere Therapeutics by 353.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,690 shares of the company’s stock worth $78,000 after buying an additional 6,773 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Travere Therapeutics during the 4th quarter worth approximately $137,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Travere Therapeutics by 32.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,511 shares of the company’s stock valued at $148,000 after acquiring an additional 4,007 shares during the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.